Plain-English translation of NCT06652672 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
The SENTRY Trial is testing a new surgical approach for early-stage colon cancer called organ-sparing surgery combined with sentinel lymph node biopsy. Instead of removing a large section of the colon (which can cause serious complications and affect quality of life), this approach uses special dye and imaging to find and check only the lymph nodes most likely to contain cancer, while removing a much smaller area of the colon. The goal is to give patients the best chance of being cancer-free while keeping their colon as intact as possible.
Standard colon cancer surgery removes a large segment of the colon and is associated with serious complications in about one-third of patients, including bowel problems that affect quality of life. This trial exists because early-stage colon cancers often have a low risk of cancer spread to lymph nodes, so a smaller, more targeted surgical approach might be safer and better for patients while still treating the cancer effectively.
You likely qualify if…
You likely don't qualify if…
If you join this trial, you would undergo the new organ-sparing surgery, which uses a special fluorescent dye to identify and remove only the lymph nodes at highest risk of containing cancer, while preserving as much of your colon as possible. The surgery is performed using minimally invasive laparoscopic or robotic techniques. You would then be followed with regular monitoring to ensure the cancer does not return, similar to standard post-cancer care.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Netherlands